

Congress of the United States
House of Representatives
Washington, DC 20515

July 14, 2021

Janet Woodcock, M.D.
Acting Commissioner
U.S. Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, M.D. 20993-0002

Dear Acting Commissioner Woodcock,


We write today regarding the FDA's "Memorandum of Understanding Addressing Certain Distributions of Compounded Drug Products" (MOU). We commend the Agency's thoughtful deliberation over the past several years to finalize this framework. As you are aware, the MOU was finalized in October of 2020 and has an enforcement date of October 26, 2021, after which pharmacies located in states that do not sign the agreement would be subject to a five percent cap on distributing compounded medications across state lines. This limitation would have dire consequences for the countless patients that rely on compounded medications and for the pharmacies located in states that, for varying reasons, cannot sign the MOU. We are writing to ask for a delay in enforcement of this policy to give the various state boards of pharmacy the necessary amount of time to review and enter into this agreement.

We understand that the National Association of Boards of Pharmacy (NABP), which is specifically mentioned in the underlying federal statute and has partnered with FDA to provide data and information on compliance, has requested a one-year delay of the October 26, 2021 enforcement date. The major pharmacy associations (NCPA, APHA, APC, NASPA), which are assisting states in the effort to get individual state boards of pharmacies to sign the MOU, have requested a two-year delay. Given the years of work that went into finalizing the MOU, we believe that a delay would be prudent to accommodate the needs of states in reviewing and complying with the MOU.


It is our understanding that a significant number of states, including large states like Texas and Florida, have identified obstacles to meeting the October 2021 deadline to sign the MOU based on available resources and state law conflicts. The situation has been greatly exacerbated by the current pandemic where meeting schedules of state boards of pharmacy have been disrupted and other pressing issues have diverted attention. In addition, many states have limited legislative sessions that hinder their ability to change state law quickly in the cases it will be needed to comply with the MOU. We have significant concerns over the potential disruption of access to compounded medications for patients who rely on out of state shipments for their healthcare needs.

We respectfully ask that you consider a delay in enforcement of this policy to give the various state boards of pharmacy the necessary amount of time to review and enter into this agreement. Thank you in advance for your prompt attention to this matter. Please do not hesitate to contact our office if we may be of assistance.

Sincerely,



Neal P. Dunn, M.D.
Member of Congress




Henry Cuellar
Member of Congress



Michael C. Burgess, M.D.
Member of Congress



Scott Peters
Member of Congress



H. Morgan Griffith
Member of Congress



Mark Pocan
Member of Congress




Markwayne Mullin
Member of Congress



Earl L. "Buddy" Carter
Member of Congress




Diana Harshbarger, Pharm. D.
Member of Congress



Jaime Herrera Beutler
Member of Congress



Chris Stewart
Member of Congress




Gary Palmer
Member of Congress



Paul A. Gosar, D.D.S
Member of Congress



Warren Davidson
Member of Congress



Ronny L. Jackson, M.D.
Member of Congress



Andy Biggs
Member of Congress